Acute humoral rejection in liver xenotransplantation

Zhongqiang ZHANG; Shuozhou LIANG; Zhongzhou SI; Haizhi QI

doi:10.3969/j.issn.1001-5256.2022.10.003

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2210-2213

PDF( 1978 KB)

Acute humoral rejection in liver xenotransplantation

DOI: 10.3969/j.issn.1001-5256.2022.10.003

Zhongqiang ZHANG^{1, 2},
Shuozhou LIANG^{1, 2},
Zhongzhou SI^{1, 2
,
,
,},
Haizhi QI^{1, 2}

1.
Department of Liver Transplantation, The Second Xiangya Hospital of Central South University, Changsha 410011, China
2.
Transplant Medicine Research Center, The Second Xiangya Hospital of Central South University, Changsha 410011, China

Research funding:

Hunan Provincial Key Research Project (2021DK2002)

More Information

Corresponding author: SI Zhongzhou, zhongzsi@csu.edu.cn(ORCID: 0000-0022-8875-9651)
Received Date: 2020-07-30
Accepted Date: 2020-08-31
Published Date: 2022-10-20

Abstract

Abstract

Liver transplantation is a curable therapy to save the life of patients with end-stage liver diseases of different causes. The serious shortage of liver donors led to the death of a large number of patients with end-stage liver disease. Genetic-engineered pigs used for xenotransplantation are one of the potential solutions to alleviate the liver donor shortage, but currently clinical application of such xenogeneic liver grafts is hindered by acute rejection, thrombocytopenia, and coagulation dysfunctions in patients. The development of genetic-engineering technology and the application of new immunosuppressants have controlled the acute rejection of liver xenotransplantation to some extent. However, acute humoral rejection may become another major issue for the long-term graft failure. This review summarized and discussed the potential and underlying mechanisms and preventive measures of acute humoral rejection in liver xenotransplantation.
- Liver Transplantation,
- Transplantation, Heterologous,
- Animals, Genetically Modified,
- Graft Rejection

FullText(HTML)

References(37)

References

[1]	BALJER BC, KOLHE S, CHAN CD, et al. Advances in image enhancement for sarcoma surgery[J]. Cancer Lett, 2020, 483: 1-11. DOI: 10.1016/j.canlet.2020.03.029.
[2]	MEIRELLES JÚNIOR RF, SALVALAGGIO P, REZENDE MB, et al. Liver transplantation: history, outcomes and perspectives[J]. Einstein (Sao Paulo), 2015, 13(1): 149-152. DOI: 10.1590/S1679-45082015RW3164.
[3]	COOPER D, WIJKSTROM M, HARIHARAN S, et al. Selection of patients for initial clinical trials of solid organ xenotransplantation[J]. Transplantation, 2017, 101(7): 1551-1558. DOI: 10.1097/TP.0000000000001582.
[4]	ZHANG X, LI X, YANG Z, et al. A review of pig liver xenotransplantation: Current problems and recent progress[J]. Xenotransplantation, 2019, 26(3): e12497. DOI: 10.1111/xen.12497.
[5]	van der Heyde MN. Liver transplantation[J]. Ned Tijdschr Geneeskd, 1968, 112(41): 1823-1827.
[6]	WOLF P, MEYER C, BOUDJEMA K, et al. The pig as a model in liver xenotransplantation[J]. Vet Res, 1997, 28(3): 217-222.
[7]	EKSER B, GRIDELLI B, TECTOR AJ, et al. Pig liver xenotransplantation as a bridge to allotransplantation: which patients might benefit?[J]. Transplantation, 2009, 88(9): 1041-1049. DOI: 10.1097/TP.0b013e3181ba0555.
[8]	PATEL MS, LOURAS N, VAGEFI PA. Liver xenotransplantation[J]. Curr Opin Organ Transplant, 2017, 22(6): 535-540. DOI: 10.1097/MOT.0000000000000459.
[9]	CIMENO A, BARTH RN, LAMATTINA JC. Advances in liver xenotransplantation[J]. Curr Opin Organ Transplant, 2018, 23(6): 615-620. DOI: 10.1097/MOT.0000000000000578.
[10]	RAMIREZ P, CHAVEZ R, MAJADO M, et al. The porcine liver supports metabolic homeostasis in the nonhuman primate: experimental study in a model of orthotopic liver transplantation from h-DAF transgenic pig to baboon[J]. Transplant Proc, 2000, 32(5): 1112-1113. DOI: 10.1016/s0041-1345(00)01150-7.
[11]	EKSER B, LONG C, ECHEVERRI GJ, et al. Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants: clinical relevance[J]. Am J Transplant, 2010, 10(2): 273-285. DOI: 10.1111/j.1600-6143.2009.02945.x.
[12]	KIM K, SCHUETZ C, ELIAS N, et al. Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons[J]. Xenotransplantation, 2012, 19(4): 256-264. DOI: 10.1111/j.1399-3089.2012.00717.x.
[13]	DOU K, WANG D, TAO K, et al. A modified heterotopic auxiliary living donor liver transplantation: report of a case[J]. Ann Hepatol, 2014, 13(3): 399-403. DOI: 10.1016/S1665-2681(19)30872-5
[14]	YEH H, MACHAIDZE Z, WAMALA I, et al. Increased transfusion-free survival following auxiliary pig liver xenotransplantation[J]. Xenotransplantation, 2014, 21(5): 454-464. DOI: 10.1111/xen.12111.
[15]	NAVARRO-ALVAREZ N, SHAH JA, ZHU A, et al. The effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotransplantation[J]. Am J Transplant, 2016, 16(6): 1715-1725. DOI: 10.1111/ajt.13647.
[16]	SHAH JA, NAVARRO-ALVAREZ N, DEFAZIO M, et al. A bridge to somewhere: 25-day survival after pig-to-baboon liver xenotransplantation[J]. Ann Surg, 2016, 263(6): 1069-1071. DOI: 10.1097/SLA.0000000000001659.
[17]	SHAH JA, PATEL MS, ELIAS N, et al. Prolonged survival following pig-to-primate liver xenotransplantation utilizing exogenous coagulation factors and costimulation blockade[J]. Am J Transplant, 2017, 17(8): 2178-2185. DOI: 10.1111/ajt.14341.
[18]	LI X, WANG Y, YANG H, et al. Liver and hepatocyte transplantation: what can pigs contribute?[J]. Front Immunol, 2021, 12: 802692. DOI: 10.3389/fimmu.2021.802692.
[19]	YANG YG, SYKES M. Xenotransplantation: current status and a perspective on the future[J]. Nat Rev Immunol, 2007, 7(7): 519-531. DOI: 10.1038/nri2099.
[20]	ZHOU Q, LI T, WANG K, et al. Current status of xenotransplantation research and the strategies for preventing xenograft rejection[J]. Front Immunol, 2022, 13: 928173. DOI: 10.3389/fimmu.2022.928173.
[21]	EKSER B, KLEIN E, HE J, et al. Genetically-engineered pig-to-baboon liver xenotransplantation: histopathology of xenografts and native organs[J]. PLoS One, 2012, 7(1): e29720. DOI: 10.1371/journal.pone.0029720.
[22]	COOPER D, EKSER B, TECTOR AJ. Immunobiological barriers to xenotransplantation[J]. Int J Surg, 2015, 23(Pt B): 211-216. DOI: 10.1016/j.ijsu.2015.06.068.
[23]	CHEN G, QIAN H, STARZL T, et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys[J]. Nat Med, 2005, 11(12): 1295-1298. DOI: 10.1038/nm1330.
[24]	ZHU A, HURST R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum[J]. Xenotransplantation, 2002, 9(6): 376-381. DOI: 10.1034/j.1399-3089.2002.02138.x.
[25]	COOPER DK. Modifying the sugar icing on the transplantation cake[J]. Glycobiology, 2016, 26(6): 571-581. DOI: 10.1093/glycob/cww028.
[26]	WANG RG, RUAN M, ZHANG RJ, et al. Antigenicity of tissues and organs from GGTA1/CMAH/β4GalNT2 triple gene knockout pigs[J]. J Biomed Res, 2018. DOI: 10.7555/JBR.32.20180018.[Online ahead of print]
[27]	Humoral reactivity of renal transplant-waitlisted patients to cells from ggta1/cmah/b4galnt2, and sla class i knockout pigs: erratum[J]. Transplantation, 2018, 102(2): e88. DOI: 10.1097/TP.0000000000002066.
[28]	LADOWSKI JM, HARA H, COOPER D. The role of slas in xenotransplantation[J]. Transplantation, 2021, 105(2): 300-307. DOI: 10.1097/TP.0000000000003303.
[29]	EKSER B, BURLAK C, WALDMAN JP, et al. Immunobiology of liver xenotransplantation[J]. Expert Rev Clin Immunol, 2012, 8(7): 621-634. DOI: 10.1586/eci.12.56.
[30]	CANDINAS D, BELLIVEAU S, KOYAMADA N, et al. T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection[J]. Transplantation, 1996, 62(12): 1920-1927. DOI: 10.1097/00007890-199612270-00042.
[31]	FOX A, MOUNTFORD J, BRAAKHUIS A, et al. Innate and adaptive immune responses to nonvascular xenografts: evidence that macrophages are direct effectors of xenograft rejection[J]. J Immunol, 2001, 166(3): 2133-2140. DOI: 10.4049/jimmunol.166.3.2133.
[32]	HAUZENBERGER E, KLOMINEK J, HOLGERSSON J. Anti-Gal IgG potentiates natural killer cell migration across porcine endothelium via endothelial cell activation and increased natural killer cell motility triggered by CD16 cross-linking[J]. Eur J Immunol, 2004, 34(4): 1154-1163. DOI: 10.1002/eji.200324568.
[33]	LI S, YAN Y, LIN Y, et al. Rapidly induced, T-cell independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells[J]. Blood, 2007, 110(12): 3926-3935. DOI: 10.1182/blood-2007-01-065482.
[34]	EZZELARAB M, GARCIA B, AZIMZADEH A, et al. The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients[J]. Transplantation, 2009, 87(6): 805-812. DOI: 10.1097/TP.0b013e318199c34f.
[35]	AL-MOHANNA FA, COLLISON KS, ALLEN SP, et al. Naive neutrophils and xenotransplantation[J]. Lancet, 1996, 348(9036): 1246. DOI: 10.1016/S0140-6736(05)65524-9.
[36]	ZHANG X, WANG Q, ZHAO J, et al. The resurgent landscape of xenotransplantation of pig organs in nonhuman primates[J]. Sci China Life Sci, 2021, 64(5): 697-708. DOI: 10.1007/s11427-019-1806-2.
[37]	RAMIREZ P, MONTOYA MJ, RIOS A, et al. Prevention of hyperacute rejection in a model of orthotopic liver xenotransplantation from pig to baboon using polytransgenic pig livers (CD55, CD59, and H-transferase)[J]. Transplant Proc, 2005, 37(9): 4103-4106. DOI: 10.1016/j.transproceed.2005.09.186.

Relative Articles

[1]	Linhui HU, Yan WANG. Clinical controversies over antiviral therapy for patients in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2024, 40(5): 875-879. doi: 10.12449/JCH240505
[2]	Yanlin LI, Yan WANG, Yingqiong ZHOU, Xueliang YANG, Na CHEN, Fangyao CHEN, Xiaojing LIU. Antiviral therapy for patients with chronic hepatitis B in the immune-tolerant phase: A systematic review[J]. Journal of Clinical Hepatology, 2021, 37(6): 1282-1287. doi: 10.3969/j.issn.1001-5256.2021.06.013
[3]	Fengxia SUN. Dynamic measurement of spleen size and liver stiffness helps to judge whether antiviral therapy is needed in the immune-tolerant phase of HBV infection[J]. Journal of Clinical Hepatology, 2021, 37(5): 1027-1027. doi: 10.3969/j.issn.1001-5256.2021.05.009
[4]	Hongyu JIA, Kezhou LIU. Antiviral therapy for patients in the immune-tolerant phase of chronic HBV infection is beneficial for preventing liver cirrhosis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1024-1025. doi: 10.3969/j.issn.1001-5256.2021.05.007
[5]	Zixin CUI, Jiayun LI, Peiyao WEI, Yunru CHEN, Jianzhou LI, Feng YE. Individualized treatment should be performed in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(6): 1277-1277. doi: 10.3969/j.issn.1001-5256.2021.06.009
[6]	Hui ZHUANG. Should patients in the immune tolerance stage of chronic hepatitis B virus infection be treated?[J]. Journal of Clinical Hepatology, 2021, 37(2): 272-277. doi: 10.3969/j.issn.1001-5256.2021.02.007
[7]	Hui ZHUANG. Correction note on the estimated number of patients in the immune-tolerant phase of hepatitis B virus infection in China and globally[J]. Journal of Clinical Hepatology, 2021, 37(4): 785-786. doi: 10.3969/j.issn.1001-5256.2021.04.012
[8]	Tingting LI, Yanfang JIANG. Patients in the immune-tolerant phase of chronic HBV infection should be precisely treated with antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(5): 1022-1023. doi: 10.3969/j.issn.1001-5256.2021.05.006
[9]	Xinyue CHEN, Aixin SONG. Antiviral therapy should be selected for patients in the immune-tolerant phase of chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(6): 1278-1278. doi: 10.3969/j.issn.1001-5256.2021.06.010
[10]	Bingliang LIN. Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load[J]. Journal of Clinical Hepatology, 2021, 37(4): 778-780. doi: 10.3969/j.issn.1001-5256.2021.04.009
[11]	Aiping WANG, Chunyang WEN. Thoughts on recommendations for immune-tolerant phase of chronic hepatitisB virus infection in Guidelines for the management of hepatitis B (version 3.3) released by the Japan Society of Hepatology[J]. Journal of Clinical Hepatology, 2021, 37(7): 1528-1528. doi: 10.3969/j.issn.1001-5256.2021.07.009
[12]	Min QUAN, Huichun XING. Antiviral therapy is not recommended in immune-tolerant phase chronic hepatitis B patients without complications[J]. Journal of Clinical Hepatology, 2021, 37(6): 1279-1280. doi: 10.3969/j.issn.1001-5256.2021.06.011
[13]	Li XIAO, Jianchun XIAN. Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally[J]. Journal of Clinical Hepatology, 2021, 37(4): 781-782. doi: 10.3969/j.issn.1001-5256.2021.04.010
[14]	Yuan HUANG. Patients in the immune-tolerant phase of chronic HBV infection should be actively treated with antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(5): 1026-1026. doi: 10.3969/j.issn.1001-5256.2021.05.008
[15]	Letian LI. Antiviral therapy should be used selectively in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(6): 1275-1276. doi: 10.3969/j.issn.1001-5256.2021.06.008
[16]	Deyang WANG, Jun JIANG, Kekai ZHAO. Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(4): 775-776. doi: 10.3969/j.issn.1001-5256.2021.04.007
[17]	Minghui LI, Yao XIE. Antiviral therapy is not recommended for patients in the immune-tolerant phase of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(4): 783-784. doi: 10.3969/j.issn.1001-5256.2021.04.011
[18]	Jia SHANG. Active antiviral therapy should be given in the immune tolerance stage of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2021, 37(4): 777-777. doi: 10.3969/j.issn.1001-5256.2021.04.008
[19]	Zhou LuLu, Liu Na, Li ChunXia, Dong Bing, Bai XiaoXiao, Zhang Nan, Xu GuangHua. Research advances in the diagnosis and treatment of patients in the immune tolerance stage of chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2019, 35(8): 1824-1827. doi: 10.3969/j.issn.1001-5256.2019.08.039
[20]	Wang Kai, Gao Wei. Research advances in immune tolerance in children receiving liver transplantation[J]. Journal of Clinical Hepatology, 2019, 35(11): 2402-2407. doi: 10.3969/j.issn.1001-5256.2019.11.005

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	卓勇佳，叶枫，唐可京，简怡飞，肖敦明，宣建伟. 中国侵袭性曲霉病患者的诊疗情况及经济负担. 中国药物经济学. 2023(01): 27-31+35 .
2.	张聪，戴钱姣，朱潇冉，潘颖璐，戴霞红. 伏立康唑与卡泊芬净治疗肝衰竭并发侵袭性肺感染的效果比较. 中国现代医生. 2021(14): 115-118 .
3.	单明珠，颜鸣菊，朱作斌，陈莹，顾兵，李颖. 2007-2019年肺部真菌感染危险因素与病原菌分布的荟萃分析. 中华医院感染学杂志. 2020(02): 174-179 .
4.	戴婧，祝存奎，孙秀媛. 慢加急性肝衰竭患者侵袭性真菌感染后的临床表现及影响因素分析. 肝脏. 2020(10): 1098-1100 .
5.	卓丽，兰芸，李粤平，陈万山，邓西龙. 实时荧光定量PCR法对肝衰竭合并侵袭性肺曲霉菌病患者的诊断价值. 实用医学杂志. 2019(18): 2946-2949 .
6.	黄锦焕，陈潮钦. 侵袭性肺曲霉菌病的诊断研究进展. 按摩与康复医学. 2017(15): 5-6 .
7.	涂雪松，涂新羽，黄福恩，胡利霞. 肝功能衰竭并发曲霉菌感染者的临床特征及相关性研究. 中华实验和临床感染病杂志(电子版). 2017(06): 591-594 .

Other cited types(5)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (701) PDF downloads(102)

Acute humoral rejection in liver xenotransplantation

DOI: 10.3969/j.issn.1001-5256.2022.10.003